Nebivolol Inhibits Superoxide Formation by NADPH Oxidase and Endothelial Dysfunction in Angiotensin II–Treated Rats

  • Matthias Oelze
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Andreas Daiber
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Ralf P. Brandes
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Marcus Hortmann
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Philip Wenzel
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Ulrich Hink
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Eberhard Schulz
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Hanke Mollnau
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Alexandra von Sandersleben
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Andrei L. Kleschyov
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Alexander Mülsch
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Huige Li
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Ulrich Förstermann
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.
  • Thomas Münzel
    From the Johannes Gutenberg University Hospital (M.O., A.D., P.W., U.H., E.S., H.M., A.L.K., A.M., T.M.), Division of Cardiology, Mainz, Germany; J.W. Goethe-University (R.P.B.), Institut für Kardiovaskuläre Physiologie, Frankfurt am Main, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes Gutenberg-Universität Mainz, Mainz, Germany; and University Hospital Eppendorf (A.v.S.), Division of Cardiology, Hamburg, Germany.

説明

<jats:p> Nebivolol is a β <jats:sub>1</jats:sub> -receptor antagonist with vasodilator and antioxidant properties. Because the vascular NADPH oxidase is an important superoxide source, we studied the effect of nebivolol on endothelial function and NADPH oxidase activity and expression in the well-characterized model of angiotensin II–induced hypertension. Angiotensin II infusion (1 mg/kg per day for 7 days) caused endothelial dysfunction in male Wistar rats and increased vascular superoxide as detected by lucigenin-derived chemiluminescence, as well as dihydroethidine staining. Vascular NADPH oxidase activity, as well as expression at the mRNA and protein level, were markedly upregulated, as well as NOS III uncoupled, as evidenced by NO synthase III inhibitor experiments and dihydroethidine staining and by markedly decreased hemoglobin–NO concentrations. Treatment with the β-receptor blocker nebivolol but not metoprolol (10 mg/kg per day for each drug) normalized endothelial function, reduced superoxide formation, increased NO bioavailability, and inhibited upregulation of the activity and expression of the vascular NADPH oxidase, as well as membrane association of NADPH oxidase subunits (Rac1 and p67 <jats:sup>phox</jats:sup> ). In addition, NOS III uncoupling was prevented. In vitro treatment with nebivolol but not atenolol or metoprolol induced a dissociation of p67 <jats:sup>phox</jats:sup> and Rac1, as well as an inhibition of NADPH oxidase activity assessed in heart membranes from angiotensin II–infused animals, as well as in homogenates of Nox1 and cytosolic subunit–transfected and phorbol ester–stimulated HEK293 cells. These findings indicate that nebivolol interferes with the assembly of NADPH oxidase. Thus, inhibitory effects of this β-blocker on vascular NADPH oxidase may explain, at least in part, its beneficial effect on endothelial function in angiotensin II–induced hypertension. </jats:p>

収録刊行物

  • Hypertension

    Hypertension 48 (4), 677-684, 2006-10

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ